meny

About Lifecare

We aim to complete the development, testing and introduction of the worlds first long term implantable micro sensor to give people with diabetes the modern tool they deserve for monitoring glucose levels.
‍
Detecting glucose by the principle of the osmotic pressure holds promise of a glucose sensing technology that is suitable for both miniaturization and long term continuous monitoring in vivo without causing patient discomfort or reducing quality of life. It also offers several major advantages compared to current blood glucose measurement technologies.

The company

Lifecare AS (Ltd.) is a privately owned, independent company that has been dedicated to the research and development of medical sensors for health monitoring since 06/07.
‍
Our headquarter is located in Bergen, Norway. The research and development is performed through our research partner across Europe.

Lifecare is listed on Oslo Stock Exchange (LIFE-ME).

The project

The Sencell-technology is protected by patents owned by Lifecare AS. These patents are granted until year 2030 and new patents are pending.
‍
The prototypes of Sencell were evaluated in -vitro to achieve performance data and to demonstrate the working principle. The pre clinical trials # 1 and # 2 were successfully completed fall-2016. Proof-of-concept was demonstrated. The results prove that the Lifecare osmotic pressure technology is able to track interstitial glucose. It provides a stable reference for the future developmental steps and will help Lifecare to further miniaturize the sensor until successful clinical evaluation in human clinical trials.

Inject and forget

Simple in use

Control

Take control of your blood sugar

Our technology provides continuous, accurate glucose data straight to you smart device.

Learn More

Management and board of directors

Management and board of directors

The Lifecare team has both the knowledge and will to make life a little bit easier for people with diabetes. Together we work to give diabetics better control of their glucose levels.

Rune Frisvold

COO

- MBA from American Graduate School of International Management
- Managing Director of Lifecare since 2012
- Previously held senior management, operational and director positions in leading enterprises
- Managed and participated in major national and international companies and projects

Christian Torp Saure

Chairman of the board

- Master of Business Administration / NHH
- Private investor since 2003
- Former partner at ABG Sundal Collier

Joacim Holter

Board member

- Chairman and CEO of Osmotex AG
- Board member in several companies
- LL.M. from the University of Bergen Norway
- Practice as Lawyer in Norway
- Member of the Lifecare BoD since 2011

Christian Hysing-Dahl

Board member

- Private investor & adviser
- Former CEO & partner at Borea
- Head of Norwegian Equities at Nordea Invest Mgmt.
- Portfolio manager at DNB
- Portfolio manager at Investa Invest & Private Eq.
- Board member in several life science companies

Prof. Dr. med. Dr. rer. nat. Andreas Pfützner

CSO

- Managing Director of PFÜTZNER Science & Health Institute GmbH, Diabetes Center & Practice, Mainz/Germany, since 2013
- Honorary Professor of Applied Clinical Research for the University of Applied Sciences, Bingen/Germany, since 2007
- Over 25 years of pharmaceutical and device development experience

Dr. rer. nat. Sanja Ramljak

QA/QC Manager

- Scientific Project Manager sciema UG, Mainz/Germany, since 2014
- Post Doctoral Fellow at German Primate Centre, Göttingen/Germany, 2008 - 2010
- PhD at the Department of Neurology, Georg-August-University, Göttingen/Germany, 2003 – 2007

Scientific Advisory Board

Prof. David C. Klonoff

Chairman, Scientific Advisory Board

- Clinical professor of Medicine, UCSF
- Editor-in-chief, DST
- Medical Director, INST
- Chairman, i.a. DTM and ADA
- Chaired i.e. FDA, NASA, US army, NIH, NSF
- Consulting i.e. Sanofi, Google and Insulin

Prof. Lutz. Heinemann

Member, Scientific Advisory Board

- Partner and Scientific Consultant, Profil
- Co-editor, DST
- Published 160 research articles
- Awarded ”Leadership in Diabetes Technology”
- Charing the EU founded project ”AP at home”

Prof. Kåre Birkeland

CMO, Scientific Advisory Board

- Professor of Internal Medicine and Endocrinology, University of Oslo
- Senior consultant in Endocrinology, Dep. of Transplantation Medicine, Rikshospitalet, Oslo University Hospita
- Chairman Advisory Board, Norwegian Diabetes Association

Development partners

CantiMED

Germany

Between 1980 and 2017, the number of people with type 1 and type 2 diabetes worldwide has more than doubled reaching 425 million people worldwide and is projected to rise to 629 million by 2045. As of today their lives are dependent on a 40+ year old technology. Diabetics deserve something better. They deserve a modern tool such as Sencell.

Nanosciences and nanotechnology belong to the newest branches of science and are regarded by many researchers as key technologies of the 21st century. By manipulation of matter on a scale of one nanometre (being one millionth of a millimetre), the historically split sciences of physics, chemistry, biology and medicine become all intertwined, making nanoscale technologies a unique field of interdisciplinary research. The cantiMED micro cantilever sensor is a patented physical force sensor that responds to surface stress changes. The extreme sensitivity of the cantilever in terms of mechanic deflection can be used for its application as a sensor.

The patented cantiMED biosensor is a new real-time diagnostic tool that is based on the nano-mechanical response of a molecular system to a selected biomarker. For many severe diseases, such as diabetes mellitus cantiMED provides a unique and proprietary diagnostic platform that establishes real-time analysis of multiple parameters with highest possible precision and robustness that can be implemented into existing point-of-care tests (POCT). In consequence. All arising IPR and new patents will belong to Lifecare (core IP and fencing IP).
Cambridge Consultants

United Kingdom

Cambridge Consultants (CC) is a world-class supplier of innovative product development engineering and technology consulting. Working from laboratories in Cambridge, UK, and Boston, USA, they have all the in-house skills needed to create an innovative concept right the way through to taking a product into manufacturing. Most of their projects deliver prototype hardware or software and trials production batches. Their technology consultants can help maximizing a product portfolio and technology roadmap.

CC works with some of the world’s largest blue-chip companies as well as with some of the smallest, innovative start-ups who want to change the status quo fast. Founded over 50 years ago, CC combines exceptional people, proven processes and excellent facilities, backed by an enviable track record of creating world-firsts, to deliver real value to our clients.

CC provides engineering product development services from idea conception to transfer to production to deliver innovative solutions with:
- Reduced time to market
- Increased return on investment
- Reduced risk